CEL-SCI Corporation: Leading the Future of Cancer Immunotherapy with Multikine®
CEL-SCI Corporation is a biotechnology leader committed to revolutionizing cancer treatment through innovative immunotherapy approaches. Founded in 1983…
CEL-SCI’s Multikine Immunotherapy Boosts 5-Year Survival Rate in Head and Neck Cancer
CEL-SCI Corporation (NYSE American: CVM) has announced new breakthrough data from its Phase 3 trial of Multikine®, an…
Geert Kersten on CEL-SCI’s Multikine and the Future of Immunotherapy – Exclusive Interview
In this exclusive interview, host Allison Godlove sits down with CEL-SCI (NYSEAMERICAN: CVM) CEO Geert Kersten to delve…
CEL-SCI Advances in Cancer Treatment with FDA Approval for Confirmatory Multikine Study
In a landmark decision, the U.S. Food and Drug Administration (FDA) has green-lighted CEL-SCI Corporation (NYSE American: CVM)…
CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
CEL-SCI recently presented its Phase 3 data at ESMO 2022, which revealed that Neoadjuvant Multikine achieved groundbreaking tumor…
Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating…
EF Hutton Initiates Coverage of Cel-Sci (CVM) with $17 Price Target Ahead of Rumored News
Tim Moore, CFA an Analyst at EF Hutton has recently published a report citing the opportunities for growth…
Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
About Cel-Sci Corporation Cel-Sci Corporation is a publicly traded biotechnology business which develops, manufactures, and markets treatments focused…
Cel-Sci Announces Multikine Immunotherapy Significantly Improves Overall Survival Benefit for Cancer Head & Neck Patients in Phase 3 Trial
Data Shows Significant Overall Survival Benefit for Cancer Patients with Multikine Treatment Regimen Followed by Surgery & Radiotherapy…